Drug intelligence / Profile preview

PBM3M3

Development stage: Unknown
Lead developer: Shanghai Jiao Tong University School of Medicine
Modality: Small Molecules
Administration: Oral

Overview

**PBM3M3** is an oral bismuth-containing quadruple rescue regimen for *Helicobacter pylori* infection. It comprises a proton-pump inhibitor, either esomeprazole or vonoprazan, at 20 mg twice daily; bismuth potassium citrate 600 mg twice daily; minocycline 50 mg three times daily; and metronidazole 400 mg three times daily. The regimen was evaluated by Shanghai Jiao Tong University School of Medicine as a lower-frequency minocycline-metronidazole alternative to conventional tetracycline-based bismuth quadruple therapy after prior *H. pylori* treatment failure.

Other names: PBM3M3PBM-3M3PBM 3M3proton-pump inhibitor + bismuth potassium citrate + minocycline + metronidazole

Targets

Bacterial RibosomeATP4A (Potassium–transporting ATPase alpha chain 1)UreaseDNA

Beyond the preview

Go deeper on PBM3M3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBM3M3.

Explore the full profile